

Session Title: #17: Bone Therapy in Breast Cancer: Why, When, and What's Next?

Session Type: Education Session

Date: Friday, June 4

Location: E Hall D1

Time: 1:00 PM - 2:15 PM

- The bone microenvironment and the potential antitumor effects of bone therapy.

Theresa Guise, MD

- Systemic therapy for bone metastasis: Past, Present, and Future

Gabriel N. Hortobagyi, MD, FACP

- Is there a role for bisphosphonates in the adjuvant setting?

Catherine H. Van Poznak, MD

Session Title: #235: Sex and the Survivor

Session Type: Extended Education Session

Date: Friday, June 4

Location: E Arie Crown Theater

Time: 1:00 PM - 3:15 PM

- Overview of Current Strategies to Prevent and Treat Cancer-Related Sexual Dysfunction

Leslie R. Schover, PhD

- Preventing and Treating Sexual Dysfunction in Women with Breast Cancer

Patricia A. Ganz, MD

- Gynecologic Approach to Women's Cancer-Related Sexual Dysfunction

Stacy Tessler Lindau, MD, MAPP

- Urologic Treatment of Men's Cancer-Related Sexual Dysfunction

John Mulhall, MD

- Sexuality in survivors of colorectal cancer

Francesco Di Fabio, MD

- SPIRIT: Peer Counseling to Promote Reproductive Health in African-American Breast Cancer Survivors

Michelle Marion Rhodes, PhD

- Sexual Impact of Being at High Genetic Risk for Cancer

Sharon L. Bober, PhD

Session Title: #236: Advances in Prevention of Major Malignancies

Session Type: Extended Education Session

Date: Friday, June 4

Location: E354b

Time: 1:00 PM - 3:15 PM

- Advances in Prevention of Major Malignancies

Victor G. Vogel, MD

- 5-alpha reductase inhibitors for prostate cancer prevention

Ian Thompson, MD

- Chemoprevention of colorectal cancer

Monica M. Bertagnolli, MD

- SERMs in the Prevention of Breast Cancer

Jack Cuzick, PhD

Session Title: #73: Molecular Profiling in Breast Cancer: Ten Years Later

Session Type: Education Session

Date: Friday, June 4

Location: E Hall D1

Time: 4:30 PM - 5:45 PM

- The Past and The Future of Molecular Profiling

Charles M. Perou, PhD

- Do Other Clinically Relevant Subtypes Exist?

Richard Iggo, MD, PhD

- How to integrate molecular profiling with standard pathology in clinical practice

George W. Sledge, MD

Session Title: #19: Cancer Fatigue and Contributing Factors: Recognition and Treatment

Session Type: Education Session

Date: Saturday, June 5

Location: E354b

Time: 8:00 AM - 9:15 AM

- Cancer-Related Fatigue: Who Gets It and How Long Does It Last?
Ann Malone Berger, RN, PhD, AOCN, FAAN
- Do Medications Work to Decrease Cancer-Related Fatigue?
Eduardo Bruera, MD
- Non Pharmacologic Interventions to Decrease Fatigue
Bernadine Cimprich, RN, PhD, CS, FAAN

Session Title: #103: Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation

Session Type: Education Session

Date: Saturday, June 5

Location: E Arie Crown Theater

Time: 8:00 AM - 9:15 AM

- Surgical options for breast cancer patients with a BRCA 1/2 mutation or a familial predisposition
Marian B.E. Menke-Pluymers, MD, PhD
- Radiation therapy and hereditary breast cancer
Abram Recht, MD
- Systemic therapy in BRCA1 and BRCA2 mutation carriers with breast cancer
Susan M. Domchek, MD

Session Title: #172: Breast Cancer - Metastatic

Session Type: Poster Discussion Session

Date: Saturday, June 5

Location: E450b

Time: 8:00 AM - 12:00 PM

- Breast Cancer - Metastatic

Anne E. Sabett, MD

1 #1012-A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).

Kathy Miller, MD

2 #1013- Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

Florence Dalenc

3 #1014-Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.

Phuong Khanh H. Morrow

4 #1015-Correlation of cyclin D1, A870G, polymorphism and clinical outcome in patients with HER2-positive, metastatic breast cancer treated with lapatinib plus capecitabine.

Melissa Janae Labonte

5 #1016-Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.

Patricia LoRusso, DO

- Discussion

David A. Cameron, MD

7 #1018-Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

Rebecca Alexandra Dent

8 #1019-A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

Steven J. Isakoff

9 #1020-Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients.

Caroline Seynaeve

10 #1021-Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

Adam Brufsky

- Discussion

Lisa A. Carey, MD

11 #1022-A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study.

Elke Jaeger

12 #1023-Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review.

Alessandra Gennari

13 #1024-Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial.

Alison Stopeck

14 #1025-Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial.

Lesley Fallowfield

15 #1026-Ibandronate in the treatment of patients (pts) with breast cancer (BC) with metastatic bone disease (MBD): Final results of a large-scale noninterventional study (NIS).

Ingo J. Diel

- Discussion

Catherine H. Van Poznak, MD

16 #1027-The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases.

Carey K. Anders

17 #1028-A graded prognostic assessment (GPA) for women with breast cancer and brain metastases.

Paul W. Sperduto

18 #1029-Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.

Anna Niwinska, MD, PhD

19 #1030-Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy.

Renata Duchnowska

- Discussion

Nancy U. Lin, MD

20 #1031-Male breast cancer in veteran population: Retrospective analysis of VACCR database.

Shanmuga Subbiah, MD, MBBS

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #239: Breast Cancer - Metastatic

Session Type: Poster Discussion Session

Date: Saturday, June 5

Location: E Hall D1

Time: 12:00 PM - 1:00 PM

- Breast Cancer - Metastatic

Anne F. Schott, MD

- Breast Cancer - Metastatic

Hope S. Rugo, MD

1 #1012-A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).

Kathy Miller, MD

2 #1013^ -Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

Florence Dalenc

3 #1014-Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.

Phuong Khanh H. Morrow

4 #1015-Correlation of cyclin D1, A870G, polymorphism and clinical outcome in patients with HER2-positive, metastatic breast cancer treated with lapatinib plus capecitabine.

Melissa Janae Labonte

5 #1016-Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.

Patricia LoRusso, DO

- Discussion

David A. Cameron, MD

7 #1018-Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

Rebecca Alexandra Dent

8 #1019-A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

Steven J. Isakoff

9 #1020-Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients.

Caroline Seynaeve

10 #1021-Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

Adam Brufsky

- Discussion

Lisa A. Carey, MD

11 #1022-A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study.

Elke Jaeger

12 #1023-Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review.

Alessandra Gennari

13 #1024-Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial.

Alison Stopeck

14 #1025-Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial.

Lesley Fallowfield

15 #1026-Ibandronate in the treatment of patients (pts) with breast cancer (BC) with metastatic bone disease (MBD): Final results of a large-scale noninterventional study (NIS).

Ingo J. Diel

- Discussion

Catherine H. Van Poznak, MD

16 #1027-The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases.

Carey K. Anders

17 #1028-A graded prognostic assessment (GPA) for women with breast cancer and brain metastases.

Paul W. Sperduto

18 #1029-Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.

Anna Niwinska, MD, PhD

19 #1030-Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy.

Renata Duchnowska

- Discussion

Nancy U. Lin, MD

20 #1031-Male breast cancer in veteran population: Retrospective analysis of VACCR database.

Shanmuga Subbiah, MD, MBBS

Session Title: #193: Breast Cancer - Local-Regional and Adjuvant Therapy

Session Type: General Poster Session

Date: Saturday, June 5

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

1A #536-DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients.

R. Charles Coombes

1B #537-Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC).

Manfred Kaufmann

1C #538-An epidemiologic study of the effect of adjuvant radiotherapy on 2D tumor characteristics and prognosis of contralateral breast cancer (CBC).

Maria E.C. Sandberg

1D #539-The use of Ki67 to predict benefit from adjuvant tamoxifen in node-negative, estrogen receptor-positive patients.

Rinat Yerushalmi

1E #540-Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin +/- trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC).

George Somlo

1F #541-Obesity and disease-free survival in patients with nodal-positive early-stage breast cancer: The ADEBAR trial.

Philip Gm Hepp

1G #542-Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial.

Michael Pollak, MD

1H #543-Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

Frederik Marme

2A #544-Prospective randomized trial comparing postoperative adjuvant concurrent versus sequential hormonal and different radiation fractionation schedule in breast cancer patients.

Mohsen Samy Barsoum

2B #545-Predictive value of a gene signature evaluated in multiple chemotherapy regimens for breast cancer.

Marcia Fournier

2C #546-Breast conservation (BCT) for DCIS: A prospective study of how MRI impacts management (MGMT).

Jennifer Lynn Marti

2D #547-Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study.

Vassilis Georgoulas

2E #548-The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis.

Ricardo H. Alvarez

2F #549-Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms.

Ian E. Krop

2G #550-Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant trials.

Fabrice Andre

2H #551-Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.

Mark Basik

3A #552-Final analysis of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group Trial (JCOG0306).

Hirofumi Mukai

3B #553-Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG): A new technology for sentinel node navigation.

Misako Nakagawa

3C #554-Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC – 3xDoc for high-risk node-negative breast cancer patients.

Christoph Thomssen

3D #555-The role of beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxicity.

Javier Munoz

3E #556-Predictive response factors (PRF) in an open, nonrandomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable HER2-negative breast cancer (BC).

Pedro Sanchez Rovira

3F #557-Comparison of 21-gene recurrence score (RS) in African-American (AA) and caucasian (C) patients with hormone receptor (HR)-positive early-stage breast cancer.

Kelli M Davis

3G #558-Effect of dose-dependent interaction between tamoxifen and antidepressants on patient adherence in breast cancer patients.

Felix W Frueh

3H #559-BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)-Cardiac safety analysis.

Daniel Rayson

4A #560-Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial.

Sirwan M Hadad, PhD, MBChB

4B #561-Evaluation of the 70-gene prognosis MammaPrint signature for the prediction of prognosis of breast cancer independently from histologic grade.

Michael Knauer

4C #562-Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14.

Judy-Anne W Chapman

4D #563-Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.

Hélène Kolesnikov-Gauthier

4E #564-Comparison of first-course PET scan against fourth-course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC).

Maribel Cotto

4F #565-Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E.

Celyne Bueno Hume

4G #566-Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.

Michael J Hassett MD MPH

4H #567-Five-year results of preoperative concurrent paclitaxel with radiation in locally advanced breast cancer (LABC).

Silvia Formenti

5A #568-Prospective study of wide local excision and endocrine therapy without radiotherapy (WORTH) for node-negative, estrogen receptor-positive early breast cancer with negative histologic margins (WORTH trial, Protocol 1): Five-year interim results.

Reiki Nishimura

5B #569-Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer.

Charles Swanton

5C #570-Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial.

Mohammed R. Keshtgar

5D #571-Cardiovascular safety of adjuvant bevacizumab for breast cancer.

Erica L. Mayer, MD

5E #572-Association of gene copy number alterations in formalin-fixed, paraffin-embedded tumors with prognostic molecular and pathologic tumor subtypes in early-stage breast cancer.

James L. Murray

5F #573-Primary endocrine therapy for early operable primary breast cancer in elderly women: Survival analysis of a large series from a single institution.

Waleed Al-Khyatt

5G #574-Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care?

Rachel A. Freedman

5H #575-Chemotherapy (CT) versus tamoxifen (T) versus chemotherapy plus tamoxifen (CTT) in patients with node-positive (N+), estrogen receptor-positive (ER+) breast cancer (bca): Very late results of an Italian multicentric trial.

Francesco Boccardo

6A #576-Randomized phase II trial of preoperative lapatinib versus placebo in HER-2-positive breast cancer.

Andrea De Censi

6B #577-Decision analysis: Excision alone versus excision plus radiation therapy for ductal carcinoma in situ.

Rinaa S. Punglia

6C #578-Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer.

Dawn L. Hershman, MD

6D #579-Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC).

Michelle E. Melisko

6E #580-Outcomes differences in tumors < 1 cm by age and breast cancer subtype.

Jennifer Keating Litton

6F #581-Adjuvant chemotherapy and lymph node irradiation in breast cancer patients with axillary lymph node micrometastases or isolated tumor cells.

Miriam Gardner

6G #582-Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS+RT).

Julie Goswami

6H #583-Cause-specific and all-cause mortality of HER2-positive, node-negative, T1a and T1b breast cancers.

Helen K. Chew

7A #584-Comorbidities' impact on survival after treatment for early breast cancer.

Lotte Holm Land

7B #585-MDR1/ABCB1 single nucleotide polymorphism (SNP) as a possible prognostic factor in breast cancer patients receiving docetaxel and doxorubicin neoadjuvant chemotherapy.

Hee Jun Kim, MD

7C #586-Correlation between quantitative HER2 protein level and pathologic complete response (pCR) in HER2-positive (+) breast cancer patients (pts) treated with neoadjuvant (NEO) dose-dense (dd) chemotherapy plus trastuzumab.

Judith Hurley

7D #587-Do older patients with T1a lesions require sentinel lymph node biopsy?

Meaghan W O'Malley

7E #588-Use of sequential FDG-PET/CT to guide extent of axillary lymph node dissection in breast cancer receiving neoadjuvant chemotherapy.

Bhumsuk Keam, MD

7F #589-Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC).

Sylvia Adams

7G #590-The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer.

Robert C. F. Leonard

7H #591-Obesity and tumor characteristics in nodal-positive early-stage breast cancer: Results of the German ADEBAR study.

Ulrich Andergassen

8A #592-Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary breast cancer.

Peter Schmid, MD, PhD

8B #593-Is the difference in reexcision rate of various margin assessment methods due solely to difference in volume excised?

Candice K. Culpepper

8C #594-Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041).

Aman Buzdar

8D #595-A prospective study to evaluate the role of 2-[18F] fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET), breast magnetic resonance imaging (MRI), and breast ultrasonography in monitoring tumor responses in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy.

Som Dave Mukherjee

8E #596-Guideline adherence rates of chemotherapy treatment for breast cancer patients treated in U.S. community oncology practices.

Kimberly A. Bergstrom

8F #597-The prognostic impact of age in patients with triple-negative breast cancer.

Cornelia Liedtke

8G #598-Utility of the vulnerable elders survey for predicting sixth-month functional decline among older patients with newly diagnosed breast cancer.

Cynthia Owusu

8H #599-Weight change during adjuvant chemotherapy regimens for breast cancer.

Rebecca M Speck

9A #600-Use of PET to assess tumor metabolism and blood flow by tumor subtype in locally advanced breast cancer.

Susan K Montgomery

9B #601-Activity of ixabepilone and PARP inhibitors in triple-negative breast cancer (TNBC) based on gene expression.

Christine E. Horak

9C #602-Evidence for change in prognostic stratification of breast tumor subtypes.

Shaheenah S. Dawood

9D #603-Is short interval mammogram necessary after breast-conservation surgery and radiation treatment in breast cancer patients?

Richard Val Hymas

9E #604-Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).

Ewa Mrozek

9F #605-What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study.

Barbara Kaye Bennett

9G #606-HER2 testing: A health economics perspective on alternative test strategies.

James A Lee

9H #607-Residual cancer burden (RCB) in breast cancer patients treated with taxane and anthracycline-based neoadjuvant chemotherapy: The effect of race.

Mariana Chavez-Mac Gregor

10A #608-Expression of forkhead-box protein A1 (FOXA1) as a significant prognostic and predictive marker for ER-positive breast cancer.

Eriko Tokunaga, MD, PhD

10B #609-The influence of mammoplasty in axillary lymphatic drainage patterns and sentinel lymph node detection.

Catherine Bouteille

10C #610-Effect of neoadjuvant alternating taxane- and anthracycline-based dose-dense regimen for operable breast cancer on prognosis in triple-negative tumors with a complete histological response.

Jacques Medioni

10D #611-Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer.

Robin Lewis Jones

10E #612-Breast cancer patients access to screening, radiotherapy, and cancer drugs in 18 European, Asian, and Latin American countries.

Nils Erik Wilking

10F #613-The impact of the radiotherapy boost in ductal carcinoma in situ.

Philip Wong

10G #614-Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer patients with isolated tumor cells or micrometastases in regional lymph nodes.

Maaïke De Boer

10H #615-Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers.

Heather L. McArthur, MD, MPH

11A #616-Substituting doxorubicin with nonpegylated liposomal doxorubicin (NPLD) in adjuvant/primary chemotherapy for early breast cancer, impact in cardiac function: A pilot study.

Neville Davidson

11B #617-Positron emission tomography (PET) and estrogen receptor (ER) ligand in patients with invasive breast cancer.

Mary Gemignani

11F #618-Notch and jak/STAT signaling pathways in breast carcinoma of luminal and basal/triple-negative immunophenotypes.

Encarna Adrover

11G #619-Germline single nucleotide polymorphisms (SNPs) in XRCC3, XRCC1, and XPD, and survival outcomes after adjuvant chemotherapy (CT) in early breast cancer (EBC) patients (pts).

Elena Castro

11H #620-Neoadjuvant chemotherapy (NCT) in operable HR-positive and TN breast cancer (BC): A randomized study comparing standard schedule to response-adapted sequence.

Christelle Jouannaud

12A #621-Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients.

Valentina Guarneri

12B #622-Meta-analysis on the impact of post-mastectomy radiotherapy on breast reconstruction outcome.

Mitchel J Barry

12F #623-Correlation of 18FDG PET-CT with SPET-CT lymphoscintigraphy to guide surgical management of the axilla in patients with T2 or T3 breast cancer.

Claude Soler

12G #624-Early operable primary breast cancer in elderly (age 70 and older) women (EPC): Changing pattern of management and clinical outcome over 36 years.

Simon J. Johnston

12H #625-High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy.

Amelia Bruce Zelnak

13A #626-Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO.

Reina Haque

13B #627-Correlation of levels of serum 25-hydroxyvitamin D (25-OHD) and lymph node positivity in operable breast cancer: A Turkish Oncology Group study.

Mustafa Kadri Altundag

13C #628-Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients.

Jose Manuel Perez-Garcia

13D #629-A phase III study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22.

Maureen E. Trudeau

13E #630-Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.

Jens Huober

13F #631-Trends in the use of implantable partial breast radiation therapy for early-stage breast cancer in the United States.

Andrea M Abbott

13G #632-Clinical relevance of TNM staging system according to breast cancer (BC) subtypes.

Yeon Hee Park

13H #633-Can tumor biomarkers predict response to neoadjuvant anthracycline/taxane chemotherapy in LABC?

John Frederick Hilton

14A #634-Prognostic value of CD44s is prognostic in the NCI randomized trial on breast conservation with 25-year follow-up.

Tu D Dan

14B #635-Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC).

Andrea Martoni

14C #636-The expression patterns of STAT-3, phosphorylated STAT-3, P38 MAP-kinase, and phosphorylated P38 MAP-kinase in triple-negative breast cancers and their prognostic significance.

Emel Yaman

14D #637-Use of trastuzumab associated with cisplatin and vinorelbine followed by docetaxel as a neoadjuvant regimen for patients with HER2-positive breast cancer.

Guido Carillio

14E #638-Twenty-year results of alternating radiotherapy and chemotherapy in nonmetastatic inflammatory breast cancer.

Eduardo Lima Pessoa

14F #639-Early therapeutic intervention based on blood tumor markers (TMs) in patients with primary breast cancer (PBC).

John Forsyth Russell Robertson

14G #640-Independent comparison of three mathematical models for predicting the risk of additional nodal metastases after positive sentinel lymph node biopsy in early breast cancer.

Yasser Z Moghaddam, MD

14H #641-Composite and component expression score correlations in ER-positive breast cancer.

Alice M. Wang, MS

15A #642-Comparison of a novel molecular assay with touch imprint and permanent histology of sentinel lymph nodes in early-stage breast cancer.

Sukamal Saha

15C #644-Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response.

Ismael Ghorbel

15D #645-Dose-dense chemotherapy in nonmetastatic breast cancer patients: A systematic review and meta-analysis.

Luisa Bonilla, Bsc, MD

15E #646-MicroRNA expression to classify breast cancer and predict relapse.

Jeannine De La Cruz

15F #647-Influence of primary systemic therapy on minimal residual disease in primary breast cancer.

Bahriye Aktas

15G #648-Neoadjuvant chemotherapy (NCT) in 466 patients for operable breast cancer : Predictive factors for pathological response.

Catherine Abrial

15H #649-Indocyanine green fluorescence imaging system for sentinel lymph node biopsy in early breast cancer patients.

Hajime Abe, MD, PhD

16A #650-Management and outcome of HER2-positive breast cancer treated with and without adjuvant trastuzumab: The Imperial College London experience.

Deep Shah

16B #651-Long-term results of a phase II trial of preoperative concurrent radiochemotherapy for breast cancers.

Marc A Bollet

16C #652-Phase II study of the combination of gemcitabine plus carboplatin as neoadjuvant treatment in locally advanced breast cancer.

Vichien Srimuninnimit

16D #653-Clinicopathologic, molecular subtype, and survival prognostic features in premenopausal breast cancer patients by age at diagnosis.

Carlos Vallejos Sologuren

16E #654-Outcome of patients with nonmetastatic breast cancer receiving nitrogen-containing bisphosphonates: A comparative analysis from the Metropolitan Detroit Cancer Surveillance System (MDCSS).

Zeina A. Nahleh

16F #655-Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: Therapeutic versus preemptive use of lamivudine.

Byeong Seok Sohn, MD, MSc

16G #656-Updated survival-based analysis using inverse probability of censoring weighted analysis (IPCW) to estimate the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer.

Jonathan Karnon

16H #657-Breast carcinoma with amplified HER2: A gene expression signature specific for trastuzumab resistance and poor prognosis.

Thaer Khoury

17A #658-An advanced computerized decision support technology to support breast multidisciplinary meetings.

Vivek Patkar

17B #659-Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells.

Denis M Collins

17C #660-The influence of the 21-gene recurrence score assay on decision-making about adjuvant chemotherapy in stage I-II estrogen receptor-positive breast cancer: Experience at a single center with a uniform treatment policy.

David Barry Geffen

17D #661-The prognostic impact of SATB1 gene expression is confined to ER-positive breast cancer.

Loreta Mavrova

17E #662-Differential response from neoadjuvant chemotherapy across breast cancer subtypes.

Hiromitsu Jinno

17F #663-Local effects of tamoxifen versus aromatase inhibitors (AI) on breast tissue: A longitudinal dynamic contrast enhanced (DCE) breast MRI cohort study.

Christiane K. Kuhl

17G #664-Microscopic disease after neoadjuvant therapy in inflammatory breast cancer.

Ashutosh Lodhi

17H #665-Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes.

Friederike Siedentopf

18A #666-Timing of genetic testing relative to breast cancer surgery.

Julia R Trosman

18B #667-Assessment of concomitant versus sequential aromatase inhibitor with radiotherapy for postmenopausal women with early-stage breast cancer.

18C #668-HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit.

Sekhar Marla

18D #669-The effects of oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort.

Foluso Olabisi Ademuyiwa

18E #670-A multicenter study to determine the optimum duration of neoadjuvant letrozole on tumor regression to permit breast-conserving surgery: Final analyses.

Robert Carpenter

18F #671-Nasal septum perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?

Audrey Mailliez

18G #672-Observational GHEA study: Adjuvant trastuzumab treatment of HER2-positive breast carcinomas in the Italian clinical setting compared to HERA trial.

Manuela Campiglio

18H #673-Association between c-myc amplification and other biologic features and prognosis in primary breast cancer.

Elisabetta Pietri

19A #674-Indocyanine green (ICG) fluorescence imaging versus radioactive colloid for sentinel lymph node identification in patients with breast cancer.

Nobumi Tagaya, MD, PhD

19B #675-Predictive factors of ductal spreading in preoperative breast cancer patients.

Kazufumi Hisamatsu

19C #676-Lymphatic and vascular invasion patterns in triple-negative breast cancer.

Sebnem Yaman

19D #677-Progesteron receptor status as a predictor of progression-free survival and overall survival in patients with early breast cancer.

Tiziana Latiano

19E #678-Comparative evaluation of two methods of chemotherapy dose calculation according to body surface area and body mass index in obese females with breast cancer.

Tamer Refaat

19F #679-The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women.

Chris E. Holmes

19G #680-Long-term outcome of phase II study of biweekly dose-dense AC followed by weekly paclitaxel and carboplatin and trastuzumab (TC & plusmn; H) based on HER2 status in large and inflammatory breast cancer (BC).

Rita S. Mehta

19H #681-A multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer.

Toshiaki Saeki

20B #683-Pathologic response rate for high-risk operable breast cancer after TNCF semi-intensive neoadjuvant chemotherapy: Updated data with long-term results.

Xavier Durando

20C #684-First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting.

Stephen K. Gruschkus

20D #685-Phase IB study of primary chemotherapy with paclitaxel, gemcitabine, and sunitinib in patients with HER2-negative stage II/III breast cancer.

Keun Seok Lee

- Breast Cancer - Local-Regional and Adjuvant Therapy

ken cho

Session Title: #194: Breast Cancer - Metastatic

Session Type: General Poster Session

Date: Saturday, June 5

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

21A #1032-Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM).

Eva M. Lepisto

21B #1033-Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy.

Mario Giuliano, MD

21C #1034-Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer.

Monica Arnedos, MD

21D #1035-Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET+LAP) versus anastrozole plus trastuzumab (ANA+TZ) as first-line treatment for postmenopausal women with HER2+ and HR+ metastatic breast cancer (MBC) from the U.K. National Health Service (NHS) perspective.

Valerie Hastings

21E #1036-Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy.

Sunil S. Badve

21F #1037-Early detection of recurrent breast cancer using metabolite profiling.

Vincent Asiago

21G #1038-A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).

Karen L. Tedesco, MD

21H #1039-Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers.

Libero Santarpia

22A #1040-Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results.

Hope S. Rugo, MD

22B #1041[^]-Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): Pooled data of extension cohorts of phase Ib/II studies.

Guy H M Jerusalem, MD, PhD

22C #1042-Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer.

David Tabagari

22D #1043-Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis.

V. Calvo

22E #1044-Use of fresh assessment of tumor-initiating cells in pleural fluid of breast cancer patients to predict overall survival.

Wendy A. Woodward

22F #1045-Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT).

Federica Cuppone

22G #1046-Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer.

Francisco J. Esteva

22H #1047-High-throughput technologies to personalize medical treatment in patients with metastatic breast cancer.

Roberta Wolp-Diniz

23A #1048^ -Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC).

Scott D. Patterson, BSc, PhD

23B #1049-Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC).

Veronique Dieras

23C #1050-Use of serum uPA change to predict PFS and overall survival in first-line trastuzumab-treated breast cancer.

Hui Ying Hou

23D #1051-Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048).

Vicente Valero

23E #1052-Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy.

Andrew M. Wardley

23F #1053-Association of receptor activator of NF-kb (RANK) expression with bone metastasis in breast carcinomas.

Daniele Santini

23G #1054-A double-blind, randomized, prospective, phase II trial of capecitabine (Cap) plus enzastaurin (Enz) versus cap plus placebo in patients (pts) with advanced breast cancer (BrCa) and prior anthracycline and taxane treatment.

Mark Clemons

23H #1055-Correlations between efficacy and early changes in biomarkers in a metastatic breast cancer (mBC) clinical trial with sunitinib malate.

Kiana Keyvanjah

24A #1056-Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer.

Shirin Khambata-Ford

24B #1057-Risk of renal failure associated with IV bisphosphonate use in patients with metastatic breast cancer.

Wendy J Langeberg

24C #1058-Age-specific trends of survival in metastatic breast cancer: Data from a population-based cancer registry in Stockholm, Sweden.

Theodoros Foukakis

24D #1059-Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.

Alessandra Fabi

24E #1060-Safety and efficacy of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast.

Palma Fedele

24F #1061-Long-term effect of fulvestrant on signaling elements in breast cancer.

Amit Agrawal

24G #1062-Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results.

Minish Jain

24H #1063-Risk factors for central nervous system (CNS) metastases in patients with stage I-III breast cancer.

Silvia P. Neciosup

25A #1064-Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC).

Robert Griffiths

25B #1065-BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies.

Martin H. Schuler

25F #1066-Pertuzumab and trastuzumab: Exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer.

Javier Cortes

25G #1067-Phase I/II study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC).

Amy Jo Chien

25H #1068-Free methylated DNA in association of clinical signs and circulating blood tumor cells in patients with breast cancer.

Christiane Matuschek

26A #1069-Survival benefit of neck dissection for patients with breast cancer with supraclavicular lymph node metastasis.

Shin-Cheh Chen, MD

26B #1070-Incorporation of a comprehensive geriatric assessment (CGA) into a randomized phase III trial for metastatic breast cancer (MBC): The PELICAN study.

Maike De Wit

26F #1071-The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer.

Tae-Yong Kim

26G #1072-Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy.

Katharina Gunzer

26H #1073-Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC).

William John Gradishar

27A #1074-A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007.

LaTrice G Vaughn

27B #1075-Breast cancer metastasis gene signature: The search for the holy grail.

Rachel E. Ellsworth

27C #1076-Effect of the novel oncomir MiR-301 on tumor proliferation and invasion in human breast cancer.

W. SHI

27D #1077-Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

Lubos B. Petruzelka

27E #1078-Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX).

Giuseppe Curigliano, MD, PhD

27F #1079-Primary tumor tissue levels of TIMP-1 and outcome following chemotherapy with docetaxel monotherapy or docetaxel in combination with gemcitabine in patients with locally advanced or metastatic breast cancer.

Charlotte Levin Tykjær Jørgensen

27G #1080-Treatment and outcome of metastatic HER2-positive breast cancer relapsing post adjuvant trastuzumab exposure.

Jonathan Krell

27H #1081-Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer.

Hiroji Iwata

28A #1082-Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A monoinstitutional experience.

Simon Spazzapan

28B #1083-Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLT1-0701: A double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (pts) with advanced breast cancer (BC).

Patricia Gomez

28C #1084-Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research.

Everardo D. Saad

28D #1085-Interim safety data on the ZICE trial: A randomized phase III, open-label, multicenter, parallel group clinical trial to evaluate and compare the efficacy, safety profile, and tolerability of oral ibandronate versus intravenous zoledronate in the treatment of patients with breast cancer with bone metastases.

Peter J. Barrett-Lee

28E #1086-Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC).

Tiffany A. Traina

28F #1087- ^{18}F -[^{18}F]fluoro-17 β -estradiol (FES)-PET to detect ER-positive tumor lesions in patients with breast cancer with a diagnostic dilemma.

Michel van Kruchten, MD, MSc

28G #1088-HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast cancer.

Sae-Won Han

28H #1089-Combination with zoledronic acid (ZA) and sunitinib (SU) to reduce severity of osteolytic lesions in bone metastases.

Christian Schem

29A #1090-Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC).

Isabel Blancas

29B #1091-Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis.

N. Ramirez

29C #1092-Characteristics of triple-negative metastatic breast cancer among older adults: A population-based analysis.

Ilene H. Zuckerman

30A #1093-Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer.

Cristiano Ferrario

30B #1094-Circulating tumor cells (CTCs) and association with survival in molecular subtypes (MST) of metastatic breast cancer (MBC).

Mark L. Graham, MD

30C #1095-Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

Mansoor N. Saleh

31A #1096-Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower

31B #1097-A phase II cross-over study of docetaxel versus vinorelbine in anthracycline-resistant, advanced breast cancer.

Constantine C. Alifrangis

31C #1098-Fulvestrant (F) as first-line palliative treatment for hormone receptor (HR)-positive metastatic breast cancer.

Rupert Bartsch

32A #1099-Analysis of truncated HER2 expression and activation in breast cancer.

Sharat Singh

32B #1100-Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial.

Zhonghua Wang

32C #1101-Prediction of response in advanced breast cancer (ABC) patients who received trastuzumab-paclitaxel (TP): HER2 FISH ratio, expression of class III beta tubulin (bTubIII), and immunoglobulin G fragment C receptor (FCGR) polymorphisms.

Jung Ryun Ahn

33A #1102-Serum-transforming growth factor- α ; (TGF- α ;) and response to lapatinib plus capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC).

Jiyoung Rhee

33B #1103-Effect of surgical treatment of primary tumor on outcome in stage IV breast cancer.

Matthew Richard Bower

33C #1104-Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guidelines (GL) for imaging work-up of patients with metastatic breast cancer: An analysis from the commercial managed care claims PharMetrics (PM) and SEER/Medicare (SM) databases.

Diane L. McNally

34A #1105-Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer.

Laura Mercatali

34B #1106-Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall survival of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AIs).

Mehmet Artac

34C #1107-Quality-of-life outcomes of patients with breast cancer in an integrative cancer treatment setting.

Edgar Donald Staren

35A #1108-Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience.

Paola Papaldo

35B #1109-Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).

Erika Paige Hamilton

35C #1110-Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.

Rita Mukhtar

35D #1111-Taiwanese patients with breast cancer with brain metastasis (BM) enrolled in the Lapatinib Expanded Access Program (LEAP).

Chiun-Sheng Huang

35E #1112-Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m² of doxorubicin (D).

Eva Muñoz

35F #1113-Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).

Víctor Freixinos

35G #1114-A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC).

Tarini Prasad Sahoo

35H #1115-A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.

Nancy Walker Peacock

36A #1116-A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).

Dimitrios Mavroudis

36B #1117-Comparison of hormone receptor and HER2 status in resected brain metastases and primary breast cancer.

Zorica Tomasevic, MD, PhD

36C #1118-Gemcitabine plus cisplatin in pretreated metastatic breast cancer.

Glaci L. Moura

36D #1119-Cardiac safety of nonpegylated liposomal doxorubicin in patients with advanced breast cancer treated with myocet plus vinorelbine or myocet plus cyclophosphamide in a randomized phase II trial.

Vito Lorusso

36E #1120-Underuse of anthracyclines in women with HER2-positive advanced breast cancer.

Valentina Rossi

36F #1121-Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).

Norikazu Masuda

36G #1122-Lack of differences in nephrotoxicity of intravenous bisphosphonates in metastatic breast cancer.

Doerte W. Luedders

36H #1123-Pathological characteristics and prognosis of a cohort of 74 patients (pts) with breast cancer (BC) with neoplastic meningitis (NM).

Nuria Kotecki

37A #1124-Predictive factors for the severity of congestive heart failure after an epirubicin-based treatment for metastatic breast cancer.

Marianne Ryberg

37B #1125-Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases.

Vera A. Gorbunova

37C #1126-Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.

Istvan Lang

37D #1127-An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.

Christine B. Brezden

37E #1128-Safety and efficacy of metronomic nonpegylated liposomal doxorubicin in heavily pretreated advanced breast cancer.

Luis Manso

37F #1129-Concomitant gemcitabine, cisplatin, anastrozole, and zoledronic acid in HER2-negative metastatic breast cancer in postmenopausal women.

Shaharyar Ahmed

37G #1130-Impact of BMI on clinical outcome of HER2-positive breast cancer.

Veronica Parolin

37H #1131-Recurrence and survival after pulmonary metastasis in triple-negative breast cancer.

Vijaya K. Gadiyaram

38A #1132-Factors associated with the choice of taxane monotherapy or combination in the management of advanced breast cancer: Results of an international observational study.

Celaletdin Camci

38B #1133-Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study.

Emmanuel S. Saloustros

38C #1134-Changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer.

Georgios Kesisis

38D #1135-Selective internal radiation therapy (SIRT) for treatment of patients with breast cancer with metastatic liver disease.

Marlies Michl

38E #1136-After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting—A single-institution experience.

Giuseppa Scandurra

38F #1137-Prospective evaluation of megestrol acetate after aromatase inhibitor failure in advanced endocrine responsive breast cancer: Preliminary results.

Jose Bines, MD

38G #1138-Biweekly liposomal pegylated doxorubicin in elderly women with advanced breast cancer: A prospective multicenter trial focusing on tolerability and cardiotoxicity.

Umberto Basso

38H #1139-Capecitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC).

Arlene Chan

39A #1140-CD4 levels as a prognostic marker for metastatic breast cancer.

Helen Jane Boyle

39B #1141-Long-term progression-free survival (PFS) in patients with metastatic breast cancer (BC) treated with tandem autologous followed by allogeneic stem cell transplantation (SCT).

Cornelia Becker

39F #1142-Midkine in the plasma as a novel breast cancer marker.

Yutaka Yamamoto, MD, PhD

39G #1143-Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results.

María Guirado-Risueño

39H #1144-Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer.

Marion Kiechle

40A #1145-Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience.

Diana Crivellari

40B #1146-Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice.

Beat Thurlimann

40F #1147-Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit?

Sercan Kadri Aksoy

40G #1148-Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.

Rachel Borson

40H #1149-Comparison of dual-probe CISH with FISH in the determination of HER2/chromosome 17 for patients with breast cancer in China.

Guoping Ren

41A #1150-HER2 as a prognostic factor in metastatic breast cancer treated with taxanes.

Eileen Parkes

41B #1151-Comparative morphometric analysis of breast-circulating tumor cells and their corresponding solid tumor cytology: A case study.

Ethan Daliere Schram

41C #1152-Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC).

Berta Alves Sousa

41D #1153-Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Tanja N. Fehm

41E #1154-Phase I study of lapatinib (L) in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer.

Nancy U. Lin, MD

41F #1155-Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC).

Giulio Metro

41G #1156-Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study.

Monica Nancy Fornier

41H #1157-Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials.

Tejal Amar Patel

Session Title: #126: Central Nervous System Metastases: From Local to Systemic Therapy

Session Type: Clinical Problems in Oncology Session

Date: Saturday, June 5

Location: E451a

Time: 3:00 PM - 4:15 PM

- The integration of surgery and radiation therapy in the management of CNS metastasis in breast cancer

Matthew G. Ewend, MD

- Systemic treatment options and opportunities in breast cancer patients with CNS mets

Nancy U. Lin, MD

- To Protect and Defend: Novel Treatment and Prevention Options for Patients with Metastatic Breast Cancer and Leptomeningeal Disease

Michael J. Glantz, MD

Session Title: #109: Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer

Session Type: Education Session

Date: Saturday, June 5

Location: N Hall B1

Time: 4:45 PM - 6:00 PM

- What's New in HER2-Positive Breast Cancer?

Lisa A. Carey, MD

- What's New in Hormone Receptor-Positive Breast Cancer?

Mitchell Dowsett, PhD

- What's New in Triple-Negative Breast Cancer?

Olufunmilayo I. Olopade, MBBS, FACP

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodj, MD

Session Title: #8: Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat

Session Type: Education Session

Date: Sunday, June 6

Location: S100a

Time: 9:45 AM - 11:00 AM

- Benefits of Adjuvant Therapy
Peter Ravdin, MD
- Estimating life expectancy and benefit from adjuvant therapy based on comorbidity
Supriya Gupta Mohile, MD, MS
- The Importance of Shared Decision-Making Regarding Adjuvant Therapy
Arash Naeim, MD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture
Douglas W. Blayney, MD
- Plenary Session including Science of Oncology Award and Lecture
Daniel F. Hayes, MD
- Plenary Session including Science of Oncology Award and Lecture
Frank McCormick, PhD, FRS
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.
Robert A Burger
- Discussion
Elizabeth A. Eisenhauer, MD
- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC)

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #215: Predictors of Response to Preoperative Therapy: Where are We?

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: N Hall B1

Time: 4:30 PM - 6:00 PM

- Predictors of Response to Preoperative Therapy: Where are We?

Antonio C. Wolff, MD, FACP

- Predictors of Response to Preoperative Therapy: Where are We?

William Fraser Symmans, MD

- Discussion: Preoperative Therapy in Operable Breast Cancer: How, When, and Why?

Gabriel N. Hortobagyi, MD, FACP

- #500-Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).

Emilio Alba

- #501-Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials.

Gunter Von Minckwitz

- #502-Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC).

Miguel Martin

- #LBA503-Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis.

Herve R. Bonnefoi, MD

- Discussion

Mitchell Dowsett, PhD

Session Title: #88: Physical Activity in Cancer Populations: What's New?

Session Type: Education Session

Date: Sunday, June 6

Location: E354b

Time: 4:45 PM - 6:00 PM

- Physical Activity and Cancer: Overview and Implications for Survivorship

Jennifer A. Ligibel, MD

- Randomized trials of exercise in cancer patients: Health-related fitness and patient-reported outcomes

Kerry S. Courneya, PhD

- Exercise Testing and Prescription for Cancer Survivors: Guidelines from the American College of Sports Medicine

Kathryn Schmitz, PhD, MPH

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #29: Controversies in Adjuvant Systemic Treatment of Early-stage Breast Cancer

Session Type: Education Session

Date: Monday, June 7

Location: N Hall B1

Time: 8:00 AM - 9:15 AM

- Tailoring Adjuvant Therapy for HER2 Negative Breast Cancer

Harold J. Burstein, MD, PhD

- Small HER2-positive Tumors: When to Add Anti-HER2 Therapy?

Ana M. Gonzalez-Angulo, MD, MSc

- Is It Ok Not to Give Chemotherapy in Node-Positive Breast Cancer?

Anthony Howell, MD

Session Title: #144: Breast Cancer - Local-Regional and Adjuvant Therapy

Session Type: Oral Abstract Session

Date: Monday, June 7

Location: N Hall B1

Time: 9:30 AM - 12:30 PM

- Breast Cancer - Local-Regional and Adjuvant Therapy

Rita Nanda, MD

- Breast Cancer - Local-Regional and Adjuvant Therapy

Seema Ahsan Khan, MD, FACS, MPH

- #CRA504-ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer.

Richard Cote

- #LBA505-Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients

David N. Krag

- #CRA506-ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node.

Armando E. Giuliano

- #507-Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer.

Kevin S. Hughes, MD, FACS

- Discussion

William C. Wood, MD

- #508-Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial.

Stephen K. L. Chia, MD

- #509-Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.

Gong Tang, PhD

- #510-Pharmacogenetics of tamoxifen in relation to disease-free survival in a dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.

Vincent O. Dezentje

- Discussion

Angelo Di Leo, MD, PhD

- #511-Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.

Kathy S. Albain

- #512-Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.

Georg Pfeiler, MD

- Discussion

Pamela Jean Goodwin, MD

Session Title: #32: Controversies in the Management of Metastatic Breast Cancer

Session Type: Education Session

Date: Monday, June 7

Location: E Hall D1

Time: 1:15 PM - 2:30 PM

- Biological evolution of breast cancer: Should a metastasis be re-biopsed?

Jonas Bergh, MD, PhD

- Integration and sequence of systemic options: How to translate clinical trial results into routine practice?

Cliff Hudis, MD

- Should cost be a consideration in the management of metastatic breast cancer?

Michael J. Hassett, MD, MPH

Session Title: #171: Breast Cancer - Local-Regional and Adjuvant Therapy

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: S403

Time: 2:00 PM - 6:00 PM

- Breast Cancer - Local-Regional and Adjuvant Therapy

Lisa Yee, MD

- Breast Cancer - Local-Regional and Adjuvant Therapy

Stephen K. L. Chia, MD

1 #LBA513-ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.

Matthew James Ellis, PhD, MB, BCh

2 #514-Impact of multifocal/multicentric versus unifocal breast cancer on local recurrence.

Ryan Woods

3 #515-Determination of clear margin in breast-conserving surgery: Is 1 mm needed?

Julien Geffrelot

5 #LBA517-Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow up.

Michael Baum

- Discussion

Seema Ahsan Khan, MD, FACS, MPH

6 #518-Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy.

Michael F. Press

7 #519-Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer.

Angelo Di Leo, MD, PhD

8 #520-Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women.

Philippe Bedard

9 #521-Clinically relevant gene signatures in triple-negative and basal-like breast cancer.

Achim Rody

10 #522-Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.

Sherene Loi

- Discussion

Antonio C. Wolff, MD, FACP

11 #523-First results from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC).

Nadia Harbeck

12 #524-Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by postmenopausal women with early-stage breast cancer.

John A. Charlson, MD

14 #526-Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors.

Jun Mao

15 #527-Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.

Karin Ribí

16 #528-Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group.

Lucia Del Mastro

- Discussion

Claudine Isaacs, MD

18 #530-Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).

Guenther G. Steger

19 #531-Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).

Heikki Joensuu, MD

- Discussion

Carlos Caldas, MD, FACP, FRCP, FMedSci

21 #533-Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.

Michael Gnant

22 #534-Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormone-responsive early breast cancer: Efficacy results from 3,714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8.

Peter C. Dubsy, MD

23 #535-Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study.

Wolfgang Janni

Session Title: #214: Circulating Tumor Cells in Breast Cancer: Where are We?

Session Type: Clinical Science Symposium

Date: Monday, June 7

Location: N Hall B1

Time: 3:00 PM - 4:30 PM

- Circulating Tumor Cells in Breast Cancer: Where are We?

Suzanne D. Conzen, MD

- Circulating Tumor Cells in Breast Cancer: Where are We?

Minetta C. Liu, MD

- Discussion

John W. Park, MD

- #1000-Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.

Antonio Giordano, MD

- #1001-Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study.

Aditya Bardia, MD, MPH

- #1002-Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results.

Sally Greenberg

- #1003-Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict increased risk for relapse: The SUCCESS trial.

Brigitte Kathrin Rack

- Discussion

Lyndsay Harris, MD

Session Title: #15: Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer

Session Type: Education Session

Date: Monday, June 7

Location: S504

Time: 4:45 PM - 6:00 PM

- Update on the genetics of pediatric survivors who develop breast cancer and tumor biology

Gail E. Tomlinson, MD, PhD

- Use of tamoxifen in Hodgkin's patients for the prevention of breast cancer

Melanie R. Palomares, MD

Session Title: #238: Breast Cancer - Local-Regional and Adjuvant Therapy

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: N Hall B1

Time: 5:00 PM - 6:00 PM

- Breast Cancer - Local-Regional and Adjuvant Therapy

Lisa Yee, MD

- Breast Cancer - Local-Regional and Adjuvant Therapy

Stephen K. L. Chia, MD

1 #LBA513-ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.

Matthew James Ellis, PhD, MB, BCh

2 #514-Impact of multifocal/multicentric versus unifocal breast cancer on local recurrence.

Ryan Woods

3 #515-Determination of clear margin in breast-conserving surgery: Is 1 mm needed?

Julien Geffrelot

5 #LBA517-Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow up.

Michael Baum

- Discussion

Seema Ahsan Khan, MD, FACS, MPH

6 #518-Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy.

Michael F. Press

7 #519-Final results of a meta-analysis testing HER2 and topoisomerase II α genes as predictors of incremental benefit from anthracyclines in breast cancer.

Angelo Di Leo, MD, PhD

8 #520-Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women.

Philippe Bedard

9 #521-Clinically relevant gene signatures in triple-negative and basal-like breast cancer.

Achim Rody

10 #522-Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.

Sherene Loi

- Discussion

Antonio C. Wolff, MD, FACP

11 #523-First results from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC).

Nadia Harbeck

12 #524-Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by postmenopausal women with early-stage breast cancer.

John A. Charlson, MD

14 #526-Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors.

Jun Mao

15 #527-Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.

Karin Ribl

16 #528-Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group.

Lucia Del Mastro

- Discussion

Claudine Isaacs, MD

18 #530-Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).

Guenther G. Steger

19 #531-Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).

Heikki Joensuu, MD

- Discussion

Carlos Caldas, MD, FACP, FRCP, FMedSci

21 #533-Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.

Michael Gnant

22 #534-Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormone-responsive early breast cancer: Efficacy results from 3,714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8.

Peter C. Dubsy, MD

23 #535-Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study.

Wolfgang Janni

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III

Kathy Miller, MD

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

Kathy Miller, MD

- Discussion: Lung Cancer - Metastatic

Charles M. Rudin, MD, PhD

- Discussion: Sarcoma
Gary K. Schwartz, MD
 - Discussion: Gastrointestinal (Noncolorectal) Cancer
C. D. Blanke, MD
 - Discussion: Head and Neck Cancer
Everett E. Vokes, MD
-

Session Title: #18: Building Bridges for Successful Breast Cancer Survivorship Care

Session Type: Education Session

Date: Tuesday, June 8

Location: E354a

Time: 8:00 AM - 9:15 AM

- Coordination of Care in Breast Cancer Survivors: An Overview
Claire Frances Snyder, PhD
 - Impact of Comorbid Conditions on Breast Cancer Survivorship
Sharon Hermes Giordano, MD
 - Information and Training Needs of Primary Care Providers to Promote Quality Care for Breast Cancer Survivors
Larissa Nekhlyudov, MD, MPH
 - Communication Strategies, Models, and Tools for Partnerships between Primary Care and Oncology Care to Provide Quality Breast Cancer Survivorship Care
Eva Grunfeld, MD, D.Phil.
-

Session Title: #145: Breast Cancer - Metastatic

Session Type: Oral Abstract Session

Date: Tuesday, June 8

Location: E Hall D1

Time: 9:30 AM - 12:30 PM

- Breast Cancer - Metastatic
Elizabeth Claire Dees, MD
- Breast Cancer - Metastatic
Herve R. Bonnefoi, MD

- #CRA1004^ -A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.

Christopher Twelves

- Discussion

Harold J. Burstein, MD, PhD

- #LBA1010-Sunitinib (SU) in combination with docetaxel (D) vs D alone for the first-line treatment of advanced breast cancer (ABC)

Jonas Bergh, MD, PhD

- #LBA1011-Phase 3 Trial of Sunitinib (SU) in Combination with Capecitabine (C) vs C in Previously Treated Advanced Breast Cancer (ABC)

John Crown

- Discussion

Kimberly L. Blackwell

- #1005-A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).

Joyce O'Shaughnessy

- #1006-Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC).

Anne F. Schott, MD

- Discussion

Hope S. Rugo, MD

- #1007-Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.

Eitan Amir

- #CRA1008-Should liver metastases of breast cancer be biopsied to improve treatment choice?

Marzia Adelia Locatelli

- #1009-Discordance in hormone receptor status in breast cancer during tumor progression.

Eva Karlsson, MD

- Discussion

Andrea L. Richardson, MD, PhD